08 Jan Alesta Therapeutics Raises €65 Million Series A Financing to Advance Oral Small Molecules for Rare Diseases

“The preclinical progress of ALE1 and ALE2 underscores the company’s potential to deliver much-needed treatment options, and we are excited to support the continued advancement of these programs in 2025 and beyond.”...